Expression of Tissue factor in Adenocarcinoma and Squamous Cell Carcinoma of the Uterine Cervix: Implications for immunotherapy with hI-con1, a factor VII-IgGFaac chimeric protein targeting tissue factor

Emiliano Cocco, Joyce Varughese, Natalia Buza, Stefania Bellone, Michelle A Glasgow, Marta Bellone, Paola Todeschini, Luisa Carrara, Dan Arin Silasi, Masoud Azodi, Peter E. Schwartz, Thomas J. Rutherford, Sergio Pecorelli, Charles J. Lockwood, Alessandro D. Santin

Research output: Contribution to journalArticle

14 Scopus citations

Abstract

Background: Cervical cancer continues to be an important worldwide health problem for women. Up to 35% of patients who are diagnosed with and appropriately treated for cervical cancer will recur and treatment results are poor for recurrent disease. Given these sobering statistics, development of novel therapies for cervical cancer remains a high priority. We evaluated the expression of Tissue Factor (TF) in cervical cancer and the potential of hI-con1, an antibody-like-molecule targeted against TF, as a novel form of immunotherapy against multiple primary cervical carcinoma cell lines with squamous- and adenocarcinoma histology.Methods: Because TF is a transmembrane receptor for coagulation factor VII/VIIa (fVII), in this study we evaluated the in vitro expression of TF in cervical carcinoma cell lines by immunohistochemistry (IHC), real time-PCR (qRT-PCR) and flow cytometry. Sensitivity to hI-con1-dependent cell-mediated-cytotoxicity (IDCC) was evaluated in 5-hrs-51chromium-release-assays against cervical cancer cell lines in vitro.Results: Cytoplasmic and/or membrane TF expression was observed in 8 out of 8 (100%) of the tumor tissues tested by IHC and in 100% (11 out of 11) of the cervical carcinoma cell lines tested by real-time-PCR and flow cytometry but not in normal cervical keratinocytes (p = 0.0023 qRT-PCR; p = 0.0042 flow cytometry). All primary cervical cancer cell lines tested overexpressing TF, regardless of their histology, were highly sensitive to IDCC (mean killing ± SD, 56.2% ± 15.9%, range, 32.4%-76.9%, p < 0.001), while negligible cytotoxicity was seen in the absence of hI-con1 or in the presence of rituximab-control-antibody. Low doses of interleukin-2 further increased the cytotoxic effect induced by hI-con1 (p = 0.025) while human serum did not significantly decrease IDCC against cervical cancer cell lines (p = 0.597).Conclusions: TF is highly expressed in squamous and adenocarcinoma of the uterine cervix. hI-con1 induces strong cytotoxicity against primary cervical cancer cell lines overexpressing TF and may represent a novel therapeutic agent for the treatment of cervical cancer refractory to standard treatment modalities.

Original languageEnglish (US)
Article number263
JournalBMC Cancer
Volume11
DOIs
StatePublished - Jun 22 2011

Fingerprint Dive into the research topics of 'Expression of Tissue factor in Adenocarcinoma and Squamous Cell Carcinoma of the Uterine Cervix: Implications for immunotherapy with hI-con1, a factor VII-IgGF<sub>aac </sub>chimeric protein targeting tissue factor'. Together they form a unique fingerprint.

  • Cite this

    Cocco, E., Varughese, J., Buza, N., Bellone, S., Glasgow, M. A., Bellone, M., Todeschini, P., Carrara, L., Silasi, D. A., Azodi, M., Schwartz, P. E., Rutherford, T. J., Pecorelli, S., Lockwood, C. J., & Santin, A. D. (2011). Expression of Tissue factor in Adenocarcinoma and Squamous Cell Carcinoma of the Uterine Cervix: Implications for immunotherapy with hI-con1, a factor VII-IgGFaac chimeric protein targeting tissue factor. BMC Cancer, 11, [263]. https://doi.org/10.1186/1471-2407-11-263